Successful etanercept therapy in therapy refractory acrodermatitis continua suppurativa Hallopeau.

Author: DiepgenThomas L, WeisshaarElke

Paper Details 
Original Abstract of the Article :
A 50-year-old patient presented with erythema, vesicles and pustules as well as interphalangeal joint pain. Acrodermatitis continua suppurativa Hallopeau was diagnosed. She was treated topically with glucocorticosteroids, calcitriol, calcipotriol, tacrolimus and bath-PUVA therapy without any clear b...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元:
https://doi.org/10.1111/j.1610-0387.2007.06332.x

データ提供:米国国立医学図書館(NLM)

Etanercept: A Potential Oasis for Acrodermatitis Continua Suppurativa

Acrodermatitis continua suppurativa (ACS) is a rare and debilitating skin condition. Imagine a desert with constant, painful sores and blisters – that's what life with ACS can feel like. This research examines the use of etanercept, a drug that blocks a specific type of protein involved in inflammation, as a treatment for a severe form of ACS called Hallopeau. The patient in this case study had tried multiple other treatments without success. Etanercept, however, provided remarkable relief, clearing her symptoms within four weeks.

This research suggests that etanercept can be a valuable treatment option for patients with refractory ACS. While further research is needed to fully understand the long-term effectiveness and safety of etanercept for ACS, this case study offers hope for patients who have struggled with this challenging condition.

A Promising Path: Etanercept for Refractory ACS

The success of etanercept in this case study suggests that it may be a viable treatment option for individuals with refractory ACS. This research is a step towards finding a more effective treatment for this debilitating condition. This is like discovering a hidden oasis in the desert – a place of healing and hope.

Finding Relief: A Journey of Hope

This research highlights the need for continued exploration of new treatment options for ACS. For patients struggling with this painful and challenging condition, finding effective treatment is a priority. This case study offers hope for patients who have not found relief with other treatments. It is a reminder that the search for solutions continues, and that even in the most challenging circumstances, hope can be found.

Dr. Camel's Conclusion

This research shows that etanercept may be a promising treatment for acrodermatitis continua suppurativa. While more research is needed, this case study offers hope for patients struggling with this difficult condition. Just as a camel relies on its instinct to find water, patients with ACS need to keep searching for effective treatments that can lead them to a path of healing.

Date :
  1. Date Completed 2007-06-27
  2. Date Revised 2015-11-19
Further Info :

Pubmed ID

17537042

DOI: Digital Object Identifier

10.1111/j.1610-0387.2007.06332.x

Related Literature

SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.